Summary The development of resistance to vincristine, actinomycin D and cisplatin has been examined in a human epidermoid lung carcinoma xenograft line (HXL 55) growing in nude mice. Treatment of HXL 55 with 1 mg kg-1 vincristine or 0.5 mg kg-1 actinomycin D once in each in vivo passage resulted in a rapid reduction in tumour responsiveness to these drugs. A partial resistance was already acquired at the 2nd transplant generation. In contrast, a gradual decrease in therapeutic response was observed with 10 mg kg 1 cisplatin. Irradiation with a local dose of 10 Gy induced no resistance. The three induced drug-resistant sublines were characterized in terms of the time course of development of resistance, the degree of induced resistance, crossresistance, growth rate and stability of the phenotype.
The development of resistance to chemotherapy is a major problem in the treatment of cancer. Tumours which are initially responsive to chemotherapy can develop resistance during treatment with cytotoxic agents. Clinically, this is characterized by short periods of remission and failure to respond to subsequent therapy. For many drugs, the mechanism for resistance is unknown, and it may depend on the origin of the cell, the degree of resistance, and the method by which resistance was selected (Houghton et al., 1985) .
While a number of investigators have selected sublines of murine and human tumours in vitro which are resistant to various drugs by repeated exposure of the target cells to a sublethal concentration of drug (Conter & Beck, 1984; Twentyman et al., 1986; Tsuruo et al., 1986) , there are only few studies of the rate at which resistance develops during in vivo treatment (Griswold et al., 1974; Schabel et al., 1978; McMillan et al., 1985) . Repeated treatments at high doses in vivo mimic the clinical situation better and may prove more applicable for the investigation of the mechanisms of resistance.
In the present study, therefore, we have investigated the development of resistance to high doses of vincristine, actinomycin D and cisplatin in a human epidermoid lung carcinoma line growing as a xenograft in nude mice. In addition to the purpose to develop resistance to the three cytotoxic agents, the parent line was also treated with repeated doses of irradiation in order to develop a further resistant subline.
Materials and methods
Nude mice NMRI (nu/nu) female mice, 6-10 weeks old, were purchased from the Breeding Center, Hannover, FRG. The animals were maintained by conventional methods in Makrolon cages at 25°C and 50% humidity. Autoclaved feed and acidified water were provided ad libitum. Tumour Tumour HXL 55 was established directly as a xenograft from an epidermoid lung carcinoma resected in a 49 year old man (Mattern et al., 1985 diameter of 8 cm in the left upper lobe, staged postoperatively as T3NIMO. Since the patient had not received any therapy, the disease progressed rapidly and he died 6 months after operation. Histologically, the human biopsy specimen and who corresponding xenograft in all passages fulfilled the WHO criteria of a poorly differentiated epidermoid lung carcinoma. Cytogenetic studies revealed a human karyotype. The detailed histology, tumour markers and general chemotherapeutic sensitivity of HXL 55 are described elsewhere Bak et al., 1987) .
Development of drug resistance
In order to develop drug resistance, the human epidermoid lung carcinoma line HXL 55 was treated in consecutive passages with single doses of 1 mg kg -1 vincristine, 0.5 mg kg-1 actinomycin D or 10 mg kg-1 cisplatin and growth delay was measured. At each tumour passage, the first treated tumour to regrow was passaged into 8-14 fresh mice. Of these mice half were treated and half served as controls. This procedure was repeated eight times. All agents were injected in a volume of 0.02 mlg 1 body wt. Photon irradiation was performed with Co60 gamma rays (Siemens, Erlangen). Dose: 10 Gy. The tumour growth was followed by measuring two diameters daily with calipers. The tumour weight was calculated by the formula (a2 x b)/2 where b was the largest diameter and a was the diameter perpendicular to b. Growth curves were plotted and the time taken for treated and control groups to double in volume was obtained. Tumour growth delay was calculated as the difference between these values. When divided by the control doubling time, it yields an estimate termed specific growth delay (Kopper & Steel, 1975) . This value can be regarded as the number of volume doubling times by which treatment delays tumours growth.
Flow cytometric analysis The xenografted tumours were dispersed into single cell suspensions and fixed in methanol. Preparation and DNAanalysis were performed as previously described , using a flow cytofluorometer (ICP 22, Phywe).
Statistical analysis
Wilcoxon rank sum test was used to compare control groups versus treated groups.
Results
Selection of drug resistant sublines Figure 1 shows the changes in growth delay produced by repeated drug treatments with each drug. With 1 mg kg 1 vincristine and 0.5mgkg-1 actinomycinD, resistance was acquired already at the 2nd transplant generation, i.e. the administration of a single dose was able to induce a partial resistance which could not be further increased by additional in vivo treatments. The growth delay (GD) dropped from 7.2 to 2.8 days for vincristine, with a reduction factor of 2.6 (GD in untreated tumour/GD in treated tumour) after 8 treatments and from 8.0 to 2.3 days for actinomycin D with a factor of 3.5 after 8 passages. Eight treatments with 10mgkg-1 cisplatin reduced the growth delay from 10.9 to 5.4 days, a factor of 2.0. The growth delays for zero previous treatments were constant during the development of resistance (data not shown). In comparison to that with vincristine or actinomycin D, resistance to cisplatin developed gradually and was still incomplete after 8 treatments.
Irradiation with a local dose of 1OGy produced no significant change in growth delay after 7 treatments. (Table I) . Houghton et al. (1985) . They exposed a human childhood rhabdomyosarcoma grown as a xenograft in immunedeprived mice to a single dose of 3 mgkg-1 vincristine and found that with this single administration a 4-fold resistance to vincristine was induced which was stable for prolonged periods in the absence of the drug.
On the other hand, sensitivity of HXL 55 to cisplatin was gradually lost by repeated drug treatment and resistance was still incomplete after 8 transplant generations. These results are consistent with other previously published studies in which a gradual decrease in therapeutic response was detected during repeated drug treatment with cisplatin (McMillan et al., 1985; Osieka & Schmidt, 1982) . Alkylating agents as well as nitrosoureas also induce a stepwise pattern of resistance development (Griswold et al., 1974; Schabel, 1976 Schabel, , 1978 Osieka & Schmidt, 1982; Berman & Steel, 1984; McMillan et al., 1985 McMillan et al., , 1987 Schmid et al., 1986) .
It is interesting to note that in bacterial chemotherapy resistance to different drugs develops also in discrete steps, and that a high degree of resistance may either build up through successive changes or be attained in a one-step change. The pattern followed is characteristic for any particular drug. Two patterns have been recognized: the so-called 'penicillin' pattern, in which high resistance is reached only through multi-step changes; and the 'streptomycin' pattern, in which high resistance may arise in a single step (Demerec, 1957) . It is also noteworthy that the resistance pattern to a certain drug follows the same pattern in all strains and species of bacteria (Demerec, 1955) or in all tumour lines independent of animal or human origin. It still remains uncertain whether the drug-resistant sublines are established by mutation or by selection of resistant cells pre-existing in the original cell population. The rapid rate at which resistance e.g. to vincristine or actinomycin D developed suggested that a pre-existent subpopulation resistant to these agents was present in the original tumour.
The importance of growth kinetics of tumours for resistance to chemotherapy is well known (for review see Steel, 1977 ). An analysis of the growth rate of the tumours indicated that resistance to the three drugs used in this study was not due to changes in the growth rate during drug treatment. This is in agreement with some studies which found no gross difference in growth rate between the parent line and the resistant sublines (Skovsgaard, 1975; McMillan et al., 1985; Bence et al., 1986) . This is in contrast to the report by Dan0 (1972) .
In our study the induced drug resistance phenotype remained fairly stable over 5 generations of in vivo passages in the absence of anticancer agents. How far these data, however, demonstrate perhaps a genetic rather than a epigenetic aetiology has to be proven.
The knowledge of patterns of cross-resistance and collateral sensitivity is valuable in the scheduling of antitumour agents and in designing optimal drug combinations. The (1980) . They described an antinomycin D-resistant line of the P 388 leukaemia which showed no cross-resistance to adriamycin. In contrast to HXL55/VCR and HXL55/AD, the line HXL55/DDP showed cross-resistance to all drugs tested. Conter & Beck (1984) have shown that each cell line displays individual patterns of resistance and cross resistance, regardless of the selecting agent. Furthermore, comparable degrees of resistance to one drug do not necessarily predict comparable degrees of cross-resistance to other drugs.
In conclusion, our data presented here show that a rapid development of resistance with vincristine and actinomycin D occurs whereas a gradual decrease in therapeutic response is achieved by repeated drug treatment with cisplatin. Each cell line displays an individual, not predictable pattern of crossresistance. Therefore, we believe that a knowledge of the emergence of drug resistance and cross-resistance could provide information for optimal drug scheduling as well as data indicating which particular drugs should be excluded from combinations or sequential therapy schedules.
